RNA Disruption and Drug Response in Breast Cancer Primary Systemic Therapy-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

RNA Disruption and Drug Response in Breast Cancer Primary Systemic Therapy

Published:2015-05-01 Issue:51 Volume:2015 Page:76-80
ISSN:1052-6773
Container-title:JNCI Monographs
language:en
Short-container-title:JNCI Monographs

Author:

Pritzker K.,Pritzker L.,Generali D.,Bottini A.,Cappelletti M. R.,Guo B.,Parissenti A.,Trudeau M.

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology,General Medicine

Link

http://academic.oup.com/jncimono/article-pdf/2015/51/76/2797109/lgv015.pdf

Reference25 articles.

1. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial

2. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009

3. Accuracy of Clinical Examination, Digital Mammogram, Ultrasound, and MRI in Determining Postneoadjuvant Pathologic Tumor Response in Operable Breast Cancer Patients

4. Intermediate Endpoints of Primary Systemic Therapy in Breast Cancer Patients

5. Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Neoadjuvant trastuzumab deruxtecan (T-DXd) with response-directed definitive therapy in early stage HER2-positive breast cancer: a phase II study protocol (SHAMROCK study);BMC Cancer;2024-01-17

2. RNA disruption is a widespread phenomenon associated with stress-induced cell death in tumour cells;Scientific Reports;2023-01-31

3. The RNA disruption assay is superior to conventional drug sensitivity assays in detecting cytotoxic drugs;Scientific Reports;2020-05-26

4. Needle Biopsy Adequacy in the Era of Precision Medicine and Value-Based Health Care;Archives of Pathology & Laboratory Medicine;2019-05-24

5. RE: RNA Disruption Assay as a Biomarker of Pathological Complete Response in Neoadjuvant Trastuzumab-Treated Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer;Journal of the National Cancer Institute;2016-07-04

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3